Rein Therapeutics Inc. Common Stock (RNTX)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with what is known. Rein Therapeutics is a pre-revenue biopharmaceutical company with 10 employees, focused on orphan pulmonary and fibrosis indications. Its lead candidate, LTI-03, is in Phase 2 for idiopathic pulmonary fibrosis, and LTI-01 has completed Phase 1b and Phase 2a in loculated pleural effusion. Those are serious unmet needs, but a pipeline is not a moat; the filed figures show no revenue and persistent losses. In FY2025, the year ended 2025-12-31, net income was -$49.9M, or -$1.96 per diluted share. In FY2024, the year ended 2024-12-31, net income was -$62.9M, or -$3.51. In FY2023, the year ended 2023-12-31, net income was -$15.7M, or -$3.42. Recent quarters remain negative: in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$6.4M, or -$0.10, and in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$5.8M, or -$0.19. No revenue is reported in the filed figures. FairStock's calculations at the 2026-10-13 close of $0.75 show a P/E of -0.45, P/B of 6.29, ROE of -96.42%, ROCE of -21.02%, D/E of 0.42, and FCF yield of -28.9% on trailing FCF of -$18.8M. The Piotroski F-Score is 1/9, Altman Z-Score is -7.50, and FairStock Score is 30/100. The 52-week range is $0.69-$2.18, so the price is near the low, but cheapness in price alone is not value when losses are large and cash flow is negative. A Graham margin of safety is absent on current numbers. The investment case rests almost entirely on clinical outcomes, which are binary and unproven. I would watch cash runway, dilution, and trial data, not the quoted price.

In plain English: Rein Therapeutics is a small healthcare company working on experimental medicines for rare lung and scarring diseases. It has no reported revenue, has lost money in each of the last four years, and burns cash, so the business looks weak today. At $0.75 a share, the price is not supported by profits or sales, so it looks expensive on current numbers and depends heavily on future clinical trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer